ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 028

A Randomized, Double-blind, Placebo-controlled Study of Anakinra in Pediatric and Adult Patients with Still’s Disease

Laura Schanberg1, Peter Nigrovic 2, Ashley Cooper 3, Winn Chatham 4, Shoghik Akoghlanian 5, Namrata Singh 6, C. Egla Rabinovich 7, Akaluck Thatayatikom 8, Alysha Taxter 9, Jonathan Hausmann 10, Milan Zdravkovic 11, Sven Ohlman 11, Henrik Andersson 11, Susanna Cederholm 12, Gunilla Huledal 11, Rayfel Schneider 13 and Fabrizio De Benedetti 14, 1Duke Children's Hospital & Health Center, Durham, North Carolina, 2Boston Children's Hospital, Boston, Massachusetts, 3Children's Mercy Kansas City, Kansas City, 4University of Alabama at Birmingham, Birmingham, 5Nationwide Children's Hospital, Columbus, 6University of Iowa Hospitals and Clinics, Iowa, Iowa, 7Duke University Hospital, Durham, 8University of Florida, Gainesville, 9Wake Forest Baptist Medical Center, Winston-Salem, 10Division of Immunology, Boston Children's Hospital; Rheumatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, 11Sobi, Stockholm, Sweden, 12Stockholm, Sweden, 13The Hospital for Sick Children, Toronto, Canada, 14Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesu', Rome, Italy

Meeting: 2020 Pediatric Rheumatology Symposium

Keywords: Anakinra, clinical trials, IL-1, randomized trials, Still's disease

  • Tweet
  • Email
  • Print
Session Information

The 2020 Pediatric Rheumatology Symposium, originally scheduled for April 29 – May 2, was postponed due to COVID-19; therefore, abstracts were not presented as scheduled.

Date: Friday, May 1, 2020

Session Title: Poster Breakout 4 – Updates on Therapeutics

Session Type: Poster Breakout Session

Session Time: 4:30PM-5:00PM

Background/Purpose: Adult-onset Still’s disease (AOSD) and systemic juvenile idiopathic arthritis (SJIA) are rare systemic disorders of auto-inflammatory nature. There is a growing understanding that SJIA and AOSD are one disease representing an age continuum of the same condition, i.e. Still’s disease. Still’s disease is associated with an activated IL-1 pathway. The anaSTILLs study (anakinra in Still´s disease) was designed to further evaluate efficacy and safety of anakinra in patients with Still´s disease across all age groups.

Methods: The anaSTILLs study was a randomized, double-blind, placebo-controlled, 12-week study including patients with active and newly diagnosed Still´s disease (within 6 months) according to adapted ILAR criteria if < 16 years of age or Yamaguchi criteria if ≥16 years of age at disease onset. Patients were randomized to anakinra 2 mg/kg (max 100 mg/day), 4 mg/kg (max 200 mg/day) or placebo. The primary objective was to demonstrate efficacy of anakinra versus placebo as assessed by ACR30 response with absence of fever at Week 2. Secondary objectives included: early onset of efficacy, sustained efficacy, time to study drug discontinuation, safety, pharmacokinetics (PK), clinical signs and biomarkers.

Results: 12 patients were randomized and received study treatment: 6 to anakinra (2 mg/kg n=2, 4 mg/kg n=4) and 6 to placebo (the study was discontinued early due to slow recruitment). One patient in the placebo group had lymphoma, not Still’s disease, and was excluded from efficacy analyses. 11 patients were analyzed for efficacy (anakinra n=6, placebo n=5), 8 were children [median (range) age (years)=4.0 (1-11)] and 3 were adults [median (range) age (years)=32.0 (25-51)]. 55% were male and the mean symptom duration was 74.2 days. All patients on anakinra but none on placebo achieved ACR30 response with absence of fever at Week 2 (p-value=0.0022). The efficacy of anakinra was supported by superiority to placebo in ACR50/70/90 responses with absence of fever at Week 2. All placebo patients discontinued the study within 6 weeks, 2 due to progressive disease, 2 due to lack of efficacy and 1 due to withdrawal by patient. Early onset of efficacy at Week 1 was observed by a numerically higher proportion of ACR responders in the anakinra group compared to placebo. ACR30/50/70/90 responses in anakinra-treated patients were sustained throughout the study period. No unexpected safety findings were observed. Serum concentrations and PK parameters of anakinra were determined at Week 12 in 2 pediatric patients. In a 1-year-old (4.1 mg/kg) and a 6-year-old (1.5 mg/kg) patient, Cmax of 2920 ng/mL and 1060 ng/ml, was reached 4.0 and 2.1 hours after administration of anakinra, respectively. CL/F and Vd/F were 139 mL/h/kg and 1187 mL/kg, and 203 mL/h/kg and 1322 mL/kg, respectively.

Conclusion: Anakinra is superior to placebo in the treatment of Still’s disease. The safety data and steady-state PK parameters are consistent with previous anakinra experience. These results confirm the benefits of anakinra treatment in patients with active, newly diagnosed Still´s disease across ages.


Disclosure: L. Schanberg, Sanofi, 1, UCB, 1, Sobi, 1, 2, CARRA, 1, BMS, 1; P. Nigrovic, Novartis, 1, 2, BMS, 1, 2, Pfizer, 1, 2, Sobi, 1, Miach Orthopedics, 1, Simcere, 1, XBiotech, 1, Quench Bio, 1, UpTiDate, 1, The American Academy of Pediatrics, 1, CARRA, 1; A. Cooper, None; W. Chatham, Sobi, 1, 2; S. Akoghlanian, None; N. Singh, The Rheumatology Research Foundation, 1, The American Heart Association, 1; C. Rabinovich, AbbVie, 1, CARRA, 1, UCB Pharma, 1, Janssen Research & Development, 1; A. Thatayatikom, None; A. Taxter, None; J. Hausmann, Novartis, 1; M. Zdravkovic, Sobi, 1, 2, 3, 4; S. Ohlman, Sobi, 1, 2; H. Andersson, Sobi, 1; S. Cederholm, Sobi, 1, 2; G. Huledal, Sobi, 1; R. Schneider, Novartis, 1, Novimmune, 1, Sobi, 1; F. De Benedetti, Novartis, 1, 2, Novimmune, 1, Sobi, 1, 2, Roche, 1, 2, Pfizer, 1, Sanofi, 1, AbbVie, 1, Novimmune/Sobi, 1.

To cite this abstract in AMA style:

Schanberg L, Nigrovic P, Cooper A, Chatham W, Akoghlanian S, Singh N, Rabinovich C, Thatayatikom A, Taxter A, Hausmann J, Zdravkovic M, Ohlman S, Andersson H, Cederholm S, Huledal G, Schneider R, De Benedetti F. A Randomized, Double-blind, Placebo-controlled Study of Anakinra in Pediatric and Adult Patients with Still’s Disease [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 4). https://acrabstracts.org/abstract/a-randomized-double-blind-placebo-controlled-study-of-anakinra-in-pediatric-and-adult-patients-with-stills-disease/. Accessed March 28, 2023.
  • Tweet
  • Email
  • Print

« Back to 2020 Pediatric Rheumatology Symposium

ACR Meeting Abstracts - https://acrabstracts.org/abstract/a-randomized-double-blind-placebo-controlled-study-of-anakinra-in-pediatric-and-adult-patients-with-stills-disease/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences